Sectors

A
Agilent Technologies, Inc.
134.29
1 x 132.49
1 x 136.23
bid
ask
+
0.70
0.52%
500 @ 04:26 PM
135.00 +0.71 (0.53%)
Ytd-1.31%
1y10.71%
132.49
day range
136.34
108.35
52 week range
160.27
Open133.78Prev Close133.59Low132.49High136.34Mkt Cap37.94B
Vol2.18MAvg Vol2.36MEPS4.98P/E26.92Forward P/E20.20
Beta1.25Short Ratio2.13Inst. Own94.05%Dividend1.01Div YieldN/A
Ex Div Date06-30Earning08-2650-d Avg124.25200-d Avg130.731yr Est160.56
Earning
DateForEstimateReportedSurprisesurprise %
2026-05-272026-041.4N/AN/AN/A
2026-02-252026-011.371.36-0.01-0.73%
2025-11-242025-101.591.59N/AN/A
2025-08-272025-071.361.370.010.74%
2025-05-282025-041.261.310.053.97%
2025-02-262025-011.271.310.043.15%
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-06Evercore ISI GroupUpgradeOutperformOutperform
2026-06-24BarclaysUpgradeOverweightOverweight
2026-06-11Piper SandlerUpgradeOverweightNeutral
2026-06-03HSBCUpgradeBuyBuy
2026-06-02B of A SecuritiesUpgradeBuyBuy
2026-05-28RBC CapitalUpgradeOutperformOutperform
Profile
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Insider Holder
DateNameRelationQuantityDescription
2024-11-26ANCHER JENSEN HENRIKOfficer90.67KStock Award(Grant)
2025-03-13FIELDS-KUNZ HEIDIDirector0.00Stock Award(Grant)
2025-11-25GONSALVES RODNEYOfficer0.00Stock Gift
2024-09-25GRAU DOMINIQUEOfficer0.00Sale
2026-03-18KOH BOON HWEEDirector63.18KStock Award(Grant)
2025-11-17MCDONNELL PADRAIGChief Executive Officer69.03KSale
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Blackrock Inc.25.90M3.46B9.17%
2026-03-30Vanguard Capital Management LLC18.38M2.46B6.51%
2026-03-30Vanguard Portfolio Management LLC14.35M1.92B5.08%
2026-03-30State Street Corporation12.76M1.70B4.52%
2026-03-30Massachusetts Financial Services Co.12.62M1.69B4.47%
2026-03-30T. Rowe Price Investment Management, Inc.8.99M1.20B3.18%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund8.98M1.20B3.18%
2026-03-30VANGUARD INDEX FUNDS-Vanguard 500 Index Fund7.19M960.00M2.54%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund6.11M815.84M2.16%
2026-03-30T. Rowe Price Mid-Cap Growth Fund, Inc.4.26M568.89M1.51%
2026-04-29VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund3.82M510.78M1.35%
2026-05-30iShares Trust-iShares Core S&P 500 ETF3.73M497.72M1.32%
Dividend
DividendDate
0.2552026-06-30
0.2552026-03-31
0.2552026-01-06
0.2482025-09-30
0.2482025-07-01
0.2482025-04-01
Split
SplitDate
1398 : 10002014-11-03